Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Read More
Tag: RMS
EMA, FDA both accept filing of Novartis’ ofatumumab
In two head-to-head studies, ofatumumab demonstrated superiority over Aubagio in patients with relapsing forms of multiple sclerosis.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
